It may thus be worthwhile to further explore the link between inflammation, aberrant methylation and the NFκB pathway to facilitate the rational design of therapeutic strategies targeting methylation and the NFκB pathway for HCC treatment. Here, NFKB1 is linked to hepatocellular carcinoma.